This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Usmani, Saad
| Item Type | Name |
|
Concept
|
Disease Progression
|
|
Academic Article
|
Multiple myeloma: is it time for biomarker-driven therapy?
|
|
Academic Article
|
Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.
|
|
Academic Article
|
Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.
|
|
Academic Article
|
Novel drug combinations for the management of relapsed/refractory multiple myeloma.
|
|
Academic Article
|
The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
|
|
Academic Article
|
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).
|
|
Academic Article
|
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.
|
|
Academic Article
|
Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
|
|
Academic Article
|
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
|
|
Academic Article
|
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
|
|
Academic Article
|
Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
|
|
Academic Article
|
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
|
|
Academic Article
|
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
|
|
Academic Article
|
Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.
|
|
Academic Article
|
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
|